Sphingosine Kinase Inhibitors and Cancer: Seeking the Golden Sword of Hercules

Overview

Journal Cancer Res

Specialty Oncology

Date 2011 Sep 24

PMID 21940750

Citations 46

Authors

Susan Pyne

Robert Bittman

Nigel J Pyne

Affiliations

Soon will be listed here.

Abstract

There is considerable evidence that sphingosine kinases play a key role in cancer progression, which might involve positive selection of cancer cells that have been provided with a survival and growth advantage as a consequence of overexpression of the enzyme. Therefore, inhibitors of sphingosine kinase represent a novel class of compounds that have potential as anticancer agents. Poor inhibitor potency is a major issue that has precluded successful translation of these compounds into the clinic. However, recent discoveries have shown that sphingosine kinase 1 is an allosteric enzyme and that some inhibitors offer improved effectiveness by inducing proteasomal degradation of the enzyme or having nanomolar potency. Herein, we provide a perspective about these recent developments and highlight the importance of translating basic pharmacologic and biochemical findings on sphingosine kinase into new drug discovery programs for treatment of cancer.

Citing Articles

Multiple sphingolipid-metabolizing enzymes modulate influenza virus replication.

McKenna S, Jung K, Wolf J, Seo Y, Hahm B Virology. 2025; 603:110367.

PMID: 39754863 PMC: 11793951. DOI: 10.1016/j.virol.2024.110367.

The Drug Transporter P-Glycoprotein and Its Impact on Ceramide Metabolism-An Unconventional Ally in Cancer Treatment.

Ung J, Kassai M, Tan S, Loughran Jr T, Feith D, Cabot M Int J Mol Sci. 2024; 25(18).

PMID: 39337312 PMC: 11432138. DOI: 10.3390/ijms25189825.

The emerging roles of sphingosine 1-phosphate and SphK1 in cancer resistance: a promising therapeutic target.

Sami Alkafaas S, Elsalahaty M, Ismail D, Ali Radwan M, Samy ElKafas S, Loutfy S Cancer Cell Int. 2024; 24(1):89.

PMID: 38419070 PMC: 10903003. DOI: 10.1186/s12935-024-03221-8.

Targeting SphK1/2 by SKI-178 inhibits prostate cancer cell growth.

Jin L, Zhu J, Yao L, Shen G, Xue B, Tao W Cell Death Dis. 2023; 14(8):537.

PMID: 37604912 PMC: 10442381. DOI: 10.1038/s41419-023-06023-4.

Differential Expression of the Sphingolipid Pathway Is Associated with Sensitivity to the PP2A Activator FTY720 in Colorectal Cancer Cell Lines.

Sciberras P, Grech L, Grech G J Clin Med. 2021; 10(21).

PMID: 34768523 PMC: 8584763. DOI: 10.3390/jcm10214999.

References

Loveridge C, Tonelli F, Leclercq T, Lim K, Long J, Berdyshev E . The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J Biol Chem. 2010; 285(50):38841-52. PMC: 2998105. DOI: 10.1074/jbc.M110.127993. View

Ren S, Babelova A, Moreth K, Xin C, Eberhardt W, Doller A . Transforming growth factor-beta2 upregulates sphingosine kinase-1 activity, which in turn attenuates the fibrotic response to TGF-beta2 by impeding CTGF expression. Kidney Int. 2009; 76(8):857-67. DOI: 10.1038/ki.2009.297. View

Lim K, Tonelli F, Li Z, Lu X, Bittman R, Pyne S . FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. J Biol Chem. 2011; 286(21):18633-40. PMC: 3099679. DOI: 10.1074/jbc.M111.220756. View

Visentin B, Vekich J, Sibbald B, Cavalli A, Moreno K, Matteo R . Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell. 2006; 9(3):225-38. DOI: 10.1016/j.ccr.2006.02.023. View

French K, Zhuang Y, Maines L, Gao P, Wang W, Beljanski V . Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther. 2010; 333(1):129-39. PMC: 2846016. DOI: 10.1124/jpet.109.163444. View

Kapitonov D, Allegood J, Mitchell C, Hait N, Almenara J, Adams J . Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res. 2009; 69(17):6915-23. PMC: 2752891. DOI: 10.1158/0008-5472.CAN-09-0664. View

Kono Y, Nishiuma T, Nishimura Y, Kotani Y, Okada T, Nakamura S . Sphingosine kinase 1 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-beta1. Am J Respir Cell Mol Biol. 2007; 37(4):395-404. DOI: 10.1165/rcmb.2007-0065OC. View

Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T . A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol. 2003; 138(7):1303-12. PMC: 1573783. DOI: 10.1038/sj.bjp.0705182. View

Antoon J, White M, Meacham W, Slaughter E, Muir S, Elliott S . Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology. 2010; 151(11):5124-35. PMC: 2954724. DOI: 10.1210/en.2010-0420. View

10.

Hait N, Allegood J, Maceyka M, Strub G, Harikumar K, Singh S . Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science. 2009; 325(5945):1254-7. PMC: 2850596. DOI: 10.1126/science.1176709. View

11.

Paugh S, Paugh B, Rahmani M, Kapitonov D, Almenara J, Kordula T . A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood. 2008; 112(4):1382-91. PMC: 2515133. DOI: 10.1182/blood-2008-02-138958. View

12.

Kennedy A, Mathews T, Kharel Y, Field S, Moyer M, East J . Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells. J Med Chem. 2011; 54(10):3524-48. PMC: 3119570. DOI: 10.1021/jm2001053. View

13.

Pyne N, Pyne S . Sphingosine 1-phosphate and cancer. Nat Rev Cancer. 2010; 10(7):489-503. DOI: 10.1038/nrc2875. View

14.

Maceyka M, Alvarez S, Milstien S, Spiegel S . Filamin A links sphingosine kinase 1 and sphingosine-1-phosphate receptor 1 at lamellipodia to orchestrate cell migration. Mol Cell Biol. 2008; 28(18):5687-97. PMC: 2546923. DOI: 10.1128/MCB.00465-08. View

15.

Alvarez S, Harikumar K, Hait N, Allegood J, Strub G, Kim E . Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature. 2010; 465(7301):1084-8. PMC: 2946785. DOI: 10.1038/nature09128. View

16.

Beljanski V, Knaak C, Smith C . A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther. 2010; 333(2):454-64. PMC: 2872961. DOI: 10.1124/jpet.109.163337. View

17.

Strub G, Paillard M, Liang J, Gomez L, Allegood J, Hait N . Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration. FASEB J. 2010; 25(2):600-12. PMC: 3023391. DOI: 10.1096/fj.10-167502. View

18.

Watson C, Long J, Orange C, Tannahill C, Mallon E, McGlynn L . High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol. 2010; 177(5):2205-15. PMC: 2966780. DOI: 10.2353/ajpath.2010.100220. View

19.

French K, Schrecengost R, Lee B, Zhuang Y, Smith S, Eberly J . Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003; 63(18):5962-9. View

20.

Lim K, Sun C, Bittman R, Pyne N, Pyne S . (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. Cell Signal. 2011; 23(10):1590-5. PMC: 3148273. DOI: 10.1016/j.cellsig.2011.05.010. View